We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-7.92%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$670M
AUM Growth
-$18.2M
Cap. Flow
-$335M
Cap. Flow %
-50.06%
Top 10 Hldgs %
86.43%
Holding
215
New
27
Increased
46
Reduced
57
Closed
68

Top Buys

Rank Stock Value
1
NRXP icon
NRX Pharmaceuticals
NRXP
+$2.55M
2
TANH icon
Tantech Holdings
TANH
+$2.26M
3
AGTC
Applied Genetic Technologies Corporation
AGTC
+$1.76M
4
ZVRA icon
Zevra Therapeutics
ZVRA
+$1.52M
5
NBEV
NewAge, Inc. Common Stock (Delaware)
NBEV
+$1.12M

Top Sells

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$17.7M
2
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$10.2M
3
ROI
RiskOn International, Inc. Common Stock
ROI
+$7.16M
4
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.75M
5
SLAI
SOLAI Ltd ADS
SLAI
+$5.55M

Sector Composition

Rank Sector Weight
1 Healthcare 7.59%
2 Technology 1.45%
3 Financials 0.54%
4 Consumer Discretionary 0.53%
5 Consumer Staples 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
151
Autolus Therapeutics
AUTL
$386M
– –
-137,239
Closed -$712K
BCLI
152
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-34,214
Closed -$2.05M
BCLI
153
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-345
Closed -$2.07M
BITO icon
154
ProShares Bitcoin Strategy ETF
BITO
$1.39B
– –
-66,000
Closed -$1.91M
BRTX icon
155
BioRestorative Therapies
BRTX
$6.79M
– –
-10,000
Closed -$43K
BTBT icon
156
Bit Digital
BTBT
$459M
– –
-4,215,852
Closed -$17.7M
CRDF icon
157
PUT
Cardiff Oncology
CRDF
$63.6M
– –
-170
Closed -$102K
CRDL
158
Cardiol Therapeutics
CRDL
$138M
– –
-99,440
Closed -$184K
CRIS icon
159
CALL
Curis
CRIS
$9.41M
– –
-7
Closed -$1.33M
CTXR icon
160
Citius Pharmaceuticals
CTXR
$13.7M
– –
-1,235
Closed -$48K
CTXR icon
161
PUT
Citius Pharmaceuticals
CTXR
$13.7M
– –
-34
Closed -$129K
KUST
162
CALL
Kustom Entertainment Inc
KUST
$639K
– –
0
– -$38K
DXR icon
163
Daxor
DXR
$62.2M
– –
-20,996
Closed -$237K
ESPR
164
DELISTED
Esperion Therapeutics
ESPR
– –
-940,400
Closed -$4.03M
EVOK
165
DELISTED
Evoke Pharma
EVOK
– –
-611
Closed -$48K
FCEL icon
166
CALL
FuelCell Energy
FCEL
$1.57B
– –
-7
Closed -$104K
ZSTK
167
ZeroStack Corp
ZSTK
$3.28M
– –
-1,900
Closed -$2.64M
GFAI icon
168
Guardforce AI
GFAI
$9.93M
– –
-3,147
Closed -$136K
GILD icon
169
CALL
Gilead Sciences
GILD
$167B
– –
-5,489
Closed -$39.9M
HEPA
170
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-20
Closed -$23K
HEPA
171
PUT
DELISTED
Hepion Pharmaceuticals
HEPA
– –
0
– -$24K
ITP icon
172
IT Tech Packaging
ITP
$2.92M
– –
-1,157
Closed -$3K
ITP icon
173
PUT
IT Tech Packaging
ITP
$2.92M
– –
-25
Closed -$6K
LSTA icon
174
PUT
Lisata Therapeutics
LSTA
$10.6M
– –
-178
Closed -$225K
MARA icon
175
Marathon Digital Holdings
MARA
$4.34B
– –
-58,049
Closed -$1.91M
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2022 Portfolio in Review

As of Q1 2022, Sabby Management held 215 positions worth $670M, down 2.6% from $688M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Sabby Management withdrew a net $335M in Q1 2022, closing 68 positions and reducing 57 holdings. Its most notable exit was Bit Digital, an estimated $17.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.6% of assets, up from 7.4% a quarter earlier, followed by Technology and Financials.

Against the trend, Sabby Management opened a new position in NRX Pharmaceuticals worth $1.92M.

  • Sabby Management's largest Q1 2022 buy was NRX Pharmaceuticals: 78,247 shares worth $1.92M.
  • Sabby Management added most to Tantech Holdings in Q1 2022, an estimated $2.26M increase.
  • Sabby Management's biggest Q1 2022 reduction was SOLAI Ltd ADS, cutting an estimated $5.55M.
  • Sabby Management fully exited Bit Digital in Q1 2022, selling an estimated $17.7M.
  • Sabby Management's ten largest holdings make up 86% of its $670M portfolio in Q1 2022.
  • Sabby Management opened 27 new positions and closed 68 in Q1 2022.
  • Sabby Management's portfolio value fell 2.6% quarter-over-quarter to $670M.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.